Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How do you approach ADT in patients with high risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
Related Questions
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
What time frame, number of PSAs, and calculator do you use for calculating PSA doubling times?
Would you ever re-irradiate the groin/inguinal region?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
How do you contour your elective obturator lymph node volume?
How do you counsel/advise patients when asked to compare ultrahypofractionated radiotherapy with the TULSA procedure?
What SBRT dose would you give to a single external iliac lymph node recurrence (1 cm size) for a patient previously treated with salvage radiation to the pelvis?
How do you talk to patients with intermediate-risk prostate cancer deciding between LDR brachytherapy (monotherapy) vs HDR mono vs SBRT vs EBRT, in terms of the comparative side effect profile of each approach?
As PARTIQoL was a negative study, what is the current role for proton therapy in the management of prostate cancer patients?
